Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders
Building the team with experienced biotech experts and renowned leaders in the ADC field
Underscores company’s commitment to progressing lead program on novel ADC target uPARAP
Copenhagen, Denmark, December 1st, 2021 – Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announced today the appointments of Carmel M. Lynch, PhD, as Chief Development Officer (CDO) and Pernille Høyrup Hemmingsen, PhD, as Chief Technology Officer(CTO). In addition, Dennis Benjamin, PhD, will support the Company as Research Fellow & Chairman of the Scientific Advisory Board (SAB).
